1.8460
+0.0120
+(0.65%)
At close: April 17 at 9:55:01 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
59,345
59,345
70,143
138,590
104,754
Cost of Revenue
16,288
16,288
12,809
38,033
22,209
Gross Profit
43,057
43,057
57,334
100,557
82,545
Operating Expense
101,411
101,411
112,135
132,271
105,242
Operating Income
-58,354
-58,354
-54,801
-31,714
-22,697
Net Non Operating Interest Income Expense
3,670
3,670
4,172
1,441
459
Other Income Expense
-10,558
-10,558
-25,542
-3,043
1,148
Pretax Income
-65,242
-65,242
-76,171
-33,316
-21,090
Tax Provision
34
34
69
276
189
Net Income Common Stockholders
-65,276
-65,276
-76,240
-33,592
-21,279
Diluted NI Available to Com Stockholders
-65,276
-65,276
-76,240
-33,592
-21,279
Basic EPS
-0.88
-0.89
-1.12
-0.51
-0.33
Diluted EPS
-0.88
-0.89
-1.12
-0.51
-0.33
Basic Average Shares
70,447.7500
73,408
68,131
65,344
64,568
Diluted Average Shares
70,447.7500
73,408
68,131
65,344
64,568
Total Operating Income as Reported
-58,519
-58,519
-68,069
-34,881
-22,697
Total Expenses
117,699
117,699
124,944
170,304
127,451
Net Income from Continuing & Discontinued Operation
-65,276
-65,276
-76,240
-33,592
-21,279
Normalized Income
-65,145.6500
-65,145.6500
-65,758.2800
-31,090.0700
-21,279
Interest Income
3,670
3,670
4,172
1,441
459
Net Interest Income
3,670
3,670
4,172
1,441
459
EBIT
-58,354
-58,354
-54,801
-31,714
-22,697
EBITDA
-53,408
-53,408
-44,878
-21,463
-16,750
Reconciled Cost of Revenue
16,288
16,288
12,809
38,033
22,209
Reconciled Depreciation
4,946
4,946
9,923
10,251
5,947
Net Income from Continuing Operation Net Minority Interest
-65,276
-65,276
-76,240
-33,592
-21,279
Total Unusual Items Excluding Goodwill
-165
-165
-13,268
-3,167
--
Total Unusual Items
-165
-165
-13,268
-3,167
--
Normalized EBITDA
-53,243
-53,243
-31,610
-18,296
-16,750
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
-34.6500
-34.6500
-2,786.2800
-665.0700
--
12/31/2021 - 5/23/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4AJ0.BE Alk-Abello A/S
19.68
+2.23%
8C5.F Coherus BioSciences, Inc.
0.8802
-4.37%
CXF.F Chimerix, Inc.
7.48
+0.27%
ITH.F Nektar Therapeutics
0.5740
+5.03%
I5X.F Precigen, Inc.
1.1700
-2.42%
LEXXW Lexaria Bioscience Corp.
0.3400
-8.11%
IPIX Innovation Pharmaceuticals Inc.
0.0002
0.00%
NEUP Neuphoria Therapeutics Inc.
5.14
+0.38%
TSVT 2seventy bio, Inc.
4.9800
+0.20%
AEON AEON Biopharma, Inc.
0.4050
+1.28%